MCID: MLG076
MIFTS: 44

Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Categories: Endocrine diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

MalaCards integrated aliases for Malignant Ovarian Surface Epithelial-Stromal Neoplasm:

Name: Malignant Ovarian Surface Epithelial-Stromal Neoplasm 12 15
Malignant Ovarian Surface Epithelial-Stromal Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2151
NCIt 50 C40026
UMLS 73 C1518236

Summaries for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

MalaCards based summary : Malignant Ovarian Surface Epithelial-Stromal Neoplasm, also known as malignant ovarian surface epithelial-stromal tumor, is related to malignant ovarian brenner tumor and hereditary site-specific ovarian cancer syndrome. An important gene associated with Malignant Ovarian Surface Epithelial-Stromal Neoplasm is TP53 (Tumor Protein P53), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Fentanyl and Dehydroepiandrosterone have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Diseases related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 malignant ovarian brenner tumor 11.4
2 hereditary site-specific ovarian cancer syndrome 11.2 BRCA1 BRCA2
3 tuberculous salpingitis 11.0 BRCA1 BRCA2 ERBB2
4 synchronous bilateral breast carcinoma 11.0 BRCA1 BRCA2 TP53
5 breast reconstruction 11.0 BRCA1 BRCA2
6 uterine body mixed cancer 11.0 ARID1A ERBB2 TP53
7 nosophobia 11.0 BRCA1 BRCA2
8 cerebellar angioblastoma 11.0 TP53 WT1
9 cancerophobia 11.0 BRCA1 BRCA2
10 papillary serous adenocarcinoma 11.0 BRCA1 KRT7 TP53
11 mutagen sensitivity 10.9 BRCA1 BRCA2 TP53
12 gastric papillary adenocarcinoma 10.9 ERBB2 TP53
13 breast squamous cell carcinoma 10.9 ERBB2 PIK3CA TP53
14 bilateral breast cancer 10.9 BRCA1 BRCA2 ERBB2
15 lobular neoplasia 10.9 BRCA1 CDH1 ERBB2
16 vulvar intraepithelial neoplasia 10.9 CDH1 MMP2 TP53
17 esophagus adenocarcinoma 10.9 ERBB2 PIK3CA TP53
18 mucoepidermoid esophageal carcinoma 10.9 CEACAM5 TP53
19 cystadenofibroma 10.9 BRCA1 BRCA2 KRT7
20 ovarian clear cell adenocarcinoma 10.9 ARID1A HNF1B PIK3CA
21 granulosa cell tumor of the ovary 10.9 ERBB2 KRT7 TP53
22 hidradenocarcinoma 10.9 ERBB2 KRT7 TP53
23 nephrogenic adenoma of urinary bladder 10.9 KRT7 PAX8
24 acinar cell carcinoma 10.9 BRCA2 KRT7 TP53
25 nasal cavity adenocarcinoma 10.9 KRAS KRT7 TP53
26 gallbladder squamous cell carcinoma 10.9 CEACAM5 ERBB2 TP53
27 uterine corpus serous adenocarcinoma 10.9 BRCA1 BRCA2 ERBB2 TP53
28 breast cystic hypersecretory carcinoma 10.9 CDH1 ERBB2
29 fallopian tube adenocarcinoma 10.8 BRCA1 BRCA2 ERBB2 TP53
30 adult hepatocellular carcinoma 10.8 PIK3CA TP53
31 sweat gland cancer 10.8 ERBB2 KRT7 TP53
32 signet ring cell adenocarcinoma 10.8 CDH1 KRT7 TP53
33 hereditary breast ovarian cancer syndrome 10.8 BRCA1 BRCA2 TP53
34 bladder squamous cell carcinoma 10.8 ERBB2 PIK3CA TP53
35 anal squamous cell carcinoma 10.8 AKT1 PIK3CA TP53
36 female breast cancer 10.8 BRCA1 BRCA2 ERBB2 TP53
37 female reproductive endometrioid cancer 10.8 KRT7 TP53 WT1
38 barrett's adenocarcinoma 10.8 ERBB2 KRAS TP53
39 microcystic meningioma 10.8 CDH1 MMP2 VEGFA
40 sporadic breast cancer 10.8 BRCA1 BRCA2 ERBB2 TP53
41 cerebral convexity meningioma 10.8 CDH1 TP53
42 endocervical adenocarcinoma 10.8 KRT7 PAX8 TP53
43 biliary tract neoplasm 10.8 KRAS KRT7 TP53
44 dysgerminoma of ovary 10.8 BRCA1 BRCA2 WT1
45 pancreatic ductal carcinoma 10.8 KRT7 TP53 VEGFA
46 acneiform dermatitis 10.8 ERBB2 KRAS PIK3CA
47 pseudomyxoma peritonei 10.8 KRAS KRT7 TP53
48 renal pelvis adenocarcinoma 10.8 CDH1 KRT7 PAX8
49 sigmoid neoplasm 10.8 CEACAM5 KRAS
50 in situ carcinoma 10.8 BRCA1 CDH1 ERBB2 TP53

Graphical network of the top 20 diseases related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm:



Diseases related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Symptoms & Phenotypes for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

GenomeRNAi Phenotypes related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.94 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.94 ARID1A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.94 BRCA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.94 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.94 BRCA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.94 BRCA1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.94 WT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.94 HNF1B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.94 PAX8
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.94 ARID1A BRCA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.94 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 HNF1B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.94 BRCA1 HNF1B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.94 ARID1A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.94 ARID1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.94 WT1 HNF1B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.94 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.94 PAX8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.94 PAX8
20 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.94 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.94 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.94 PAX8
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.94 ARID1A PAX8 BRCA1 WT1 HNF1B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.94 WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.94 HNF1B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.94 HNF1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.94 BRCA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.94 BRCA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.94 ARID1A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.94 HNF1B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.94 HNF1B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.94 PAX8
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.94 WT1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.94 PAX8
35 Decreased viability in esophageal squamous lineage GR00235-A 9.73 KRAS KRT7 MMP2 PAX8 BRCA1 PIK3CA

MGI Mouse Phenotypes related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 WT1 BRCA2 ERBB2 CDH1 ACSBG1 ARID1A
2 growth/size/body region MP:0005378 10.46 WT1 VEGFA CDH1 BRCA2 ERBB2 ARID1A
3 endocrine/exocrine gland MP:0005379 10.44 WT1 BRCA2 ERBB2 CDH1 ACSBG1 ARID1A
4 cardiovascular system MP:0005385 10.42 WT1 VEGFA CDH1 ERBB2 ARID1A AKT1
5 embryo MP:0005380 10.42 WT1 BRCA2 ERBB2 CDH1 ARID1A AKT1
6 cellular MP:0005384 10.41 VEGFA WT1 BRCA1 CDH1 BRCA2 ERBB2
7 mortality/aging MP:0010768 10.4 WT1 VEGFA CDH1 BRCA2 ERBB2 ARID1A
8 immune system MP:0005387 10.35 VEGFA WT1 BRCA1 CDH1 BRCA2 ARID1A
9 neoplasm MP:0002006 10.23 WT1 BRCA2 ERBB2 CDH1 ARID1A AKT1
10 integument MP:0010771 10.22 VEGFA BRCA1 CDH1 BRCA2 ERBB2 AKT1
11 muscle MP:0005369 10.22 WT1 VEGFA ERBB2 ARID1A AKT1 BRCA1
12 digestive/alimentary MP:0005381 10.19 VEGFA BRCA1 CDH1 BRCA2 ERBB2 AREG
13 nervous system MP:0003631 10.17 VEGFA BRCA1 BRCA2 ERBB2 ARID1A AKT1
14 normal MP:0002873 10.15 WT1 VEGFA CDH1 BRCA2 ERBB2 ARID1A
15 craniofacial MP:0005382 10.14 VEGFA ERBB2 ARID1A KRAS MMP2 PAX8
16 limbs/digits/tail MP:0005371 10.11 VEGFA BRCA1 BRCA2 ERBB2 KRAS TP53
17 reproductive system MP:0005389 10.1 WT1 BRCA2 ERBB2 CDH1 ACSBG1 ARID1A
18 no phenotypic analysis MP:0003012 10.06 VEGFA WT1 CDH1 ARID1A ESS2 KRAS
19 renal/urinary system MP:0005367 9.92 VEGFA WT1 BRCA1 KRT7 HNF1B KRAS
20 respiratory system MP:0005388 9.76 VEGFA WT1 BRCA1 ERBB2 AKT1 MMP2
21 skeleton MP:0005390 9.73 VEGFA BRCA2 ERBB2 BRCA1 ARID1A AKT1
22 vision/eye MP:0005391 9.28 VEGFA AREG ARID1A MMP2 KRAS TP53

Drugs & Therapeutics for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Drugs for Malignant Ovarian Surface Epithelial-Stromal Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
3 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
4 Adjuvants, Anesthesia Phase 3
5 Analgesics Phase 3
6 Analgesics, Opioid Phase 3
7 Anesthetics Phase 3
8 Anesthetics, General Phase 3
9 Anesthetics, Intravenous Phase 3
10 Central Nervous System Depressants Phase 3
11 Liver Extracts Phase 3,Phase 1,Not Applicable
12 Narcotics Phase 3
13 Peripheral Nervous System Agents Phase 3
14 Adjuvants, Immunologic Phase 3,Phase 2
15 Cola Nutraceutical Phase 3,Phase 1,Phase 2,Not Applicable
16 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 3
17
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
18
Paclitaxel Approved, Vet_approved Phase 2,Phase 1,Not Applicable 33069-62-4 36314
19
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
20
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
21 Fondaparinux Approved, Investigational Phase 2 104993-28-4
22
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
23
Amifostine Approved, Investigational Phase 2,Phase 1 20537-88-6 2141
24
Etoposide Approved Phase 2 33419-42-0 36462
25
Ifosfamide Approved Phase 2 3778-73-2 3690
26
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
27
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
28
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
29
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
30
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
31
Squalamine Investigational Phase 2 148717-90-2
32 Angiogenesis Inhibitors Phase 2,Phase 1
33 Angiogenesis Modulating Agents Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 2,Phase 1
35 Anti-Infective Agents Phase 2,Phase 1
36 Protective Agents Phase 2,Phase 1
37 Albumin-Bound Paclitaxel Phase 2,Phase 1,Not Applicable
38 Antimitotic Agents Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 2,Phase 1,Not Applicable
40 Antibodies Phase 2,Phase 1
41 Antibodies, Monoclonal Phase 2,Phase 1
42 Endothelial Growth Factors Phase 2,Phase 1
43 Immunoglobulin G Phase 2,Phase 1
44 Immunoglobulins Phase 2,Phase 1
45 Mitogens Phase 2,Phase 1
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
47 Anticoagulants Phase 2
48 Antithrombin III Phase 2
49 Antithrombins Phase 2
50 Factor Xa Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
3 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer Unknown status NCT00021385 Phase 2 carboplatin;squalamine lactate
4 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
5 Paclitaxel in Treating Patients With Ovarian Stromal Cancer Completed NCT00006227 Phase 2 Paclitaxel
6 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
7 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
8 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
9 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2 rucaparib (CO-338; formally AG-014699 or PF-01367338)
10 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
11 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
12 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
13 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
14 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
15 Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer Withdrawn NCT00562185 Phase 1, Phase 2 carboplatin;doxorubicin hydrochloride
16 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
17 Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed NCT00408655 Phase 1 paclitaxel;carboplatin;temsirolimus
18 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
19 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery Completed NCT00842452 Phase 1 topotecan hydrochloride
20 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
21 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
22 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
23 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
24 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
25 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
26 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
27 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
28 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1
29 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
30 LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer Completed NCT00005858 Phase 1
31 BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer Completed NCT00005807 Phase 1 ixabepilone
32 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
33 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
34 Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer Withdrawn NCT00118300 Phase 1 capecitabine
35 Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757263
36 Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer Unknown status NCT00601406 Not Applicable
37 Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors Completed NCT01572467
38 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
39 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Completed NCT01126346 Not Applicable
40 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer Completed NCT01764789 Not Applicable
41 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
42 Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer Completed NCT01216813
43 Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer Completed NCT01170299 Not Applicable
44 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919
45 Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors Completed NCT00433602
46 Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer Completed NCT00383279 Not Applicable
47 Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer Completed NCT00295945 fentanyl citrate;hydromorphone hydrochloride;ropivacaine hydrochloride
48 Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer Completed NCT00253708 Not Applicable
49 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
50 Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer Completed NCT00003763 Not Applicable

Search NIH Clinical Center for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Genetic Tests for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Anatomical Context for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

MalaCards organs/tissues related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm:

41
Breast, Liver, Lung, Endothelial, Prostate, Ovary, Colon

Publications for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Variations for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Expression for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Search GEO for disease gene expression data for Malignant Ovarian Surface Epithelial-Stromal Neoplasm.

Pathways for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Pathways related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 AKT1 AREG BRCA1 BRCA2 ERBB2 KRAS
2
Show member pathways
13.55 AKT1 AREG BRCA1 ERBB2 HNF1B KRAS
3
Show member pathways
13.53 AKT1 ERBB2 HNF1B KRAS KRT7 MMP2
4
Show member pathways
13.39 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
5
Show member pathways
12.99 AKT1 AREG BRCA1 ERBB2 KRAS PIK3CA
6 12.79 AKT1 AREG ERBB2 KRAS TP53 VEGFA
7
Show member pathways
12.76 AKT1 CDH1 KRAS PIK3CA VEGFA
8
Show member pathways
12.76 AKT1 ERBB2 KRAS PIK3CA TP53
9
Show member pathways
12.73 AKT1 CDH1 ERBB2 KRAS PIK3CA TP53
10
Show member pathways
12.72 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
11
Show member pathways
12.7 AKT1 KRAS MMP2 PIK3CA VEGFA
12
Show member pathways
12.61 AKT1 KRAS PIK3CA TP53 VEGFA
13
Show member pathways
12.61 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
14
Show member pathways
12.6 AKT1 AREG BRCA2 CDH1 ERBB2 KRAS
15
Show member pathways
12.54 AKT1 ERBB2 KRAS PIK3CA TP53
16 12.54 BRCA1 ERBB2 KRAS PIK3CA TP53 VEGFA
17
Show member pathways
12.52 AKT1 AREG CDH1 ERBB2 KRAS MMP2
18
Show member pathways
12.47 AKT1 ERBB2 KRAS PIK3CA TP53
19
Show member pathways
12.47 AKT1 AREG ERBB2 KRAS PIK3CA TP53
20 12.44 AKT1 KRAS PIK3CA TP53
21
Show member pathways
12.42 AKT1 BRCA1 KRAS PIK3CA VEGFA
22 12.38 AKT1 BRCA2 CDH1 ERBB2 KRAS MMP2
23
Show member pathways
12.35 AKT1 ERBB2 KRAS PIK3CA
24 12.3 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
25
Show member pathways
12.27 AKT1 AREG KRAS VEGFA
26
Show member pathways
12.25 AKT1 KRAS TP53 VEGFA
27
Show member pathways
12.22 AKT1 KRAS PIK3CA TP53
28 12.21 AKT1 KRAS PIK3CA TP53
29 12.2 AKT1 CDH1 KRAS MMP2 TP53 VEGFA
30
Show member pathways
12.18 AKT1 ERBB2 KRAS PIK3CA
31
Show member pathways
12.18 AKT1 KRAS PIK3CA TP53
32 12.17 AKT1 ERBB2 KRAS PIK3CA TP53
33
Show member pathways
12.15 AKT1 ERBB2 MMP2 PIK3CA
34 12.12 AKT1 MMP2 PIK3CA TP53 VEGFA
35 12.1 AKT1 KRAS PIK3CA TP53
36 12.1 AKT1 BRCA1 BRCA2 CDH1 KRAS TP53
37
Show member pathways
12.09 AKT1 AREG BRCA1 CDH1 KRAS PIK3CA
38
Show member pathways
12.07 AKT1 ERBB2 PIK3CA TP53
39 12.05 AKT1 KRAS PIK3CA TP53
40 12.03 AKT1 KRAS PIK3CA TP53
41 12.03 AKT1 ERBB2 KRAS PIK3CA TP53
42 12.02 AKT1 MMP2 TP53 VEGFA
43
Show member pathways
11.99 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
44 11.94 AKT1 KRAS MMP2 PIK3CA VEGFA
45 11.93 AKT1 ERBB2 PIK3CA VEGFA
46
Show member pathways
11.83 BRCA1 BRCA2 TP53
47
Show member pathways
11.83 AKT1 KRAS PIK3CA
48 11.79 AKT1 BRCA1 ERBB2 PIK3CA TP53
49 11.74 AKT1 PAX8 PIK3CA
50
Show member pathways
11.72 AKT1 PIK3CA TP53

GO Terms for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Cellular components related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 AKT1 AREG ARID1A BRCA1 BRCA2 ERBB2

Biological processes related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 AREG BRCA2 ERBB2 TP53
2 negative regulation of apoptotic process GO:0043066 9.87 AKT1 CEACAM5 ERBB2 HNF1B TP53 VEGFA
3 positive regulation of protein phosphorylation GO:0001934 9.85 AKT1 ERBB2 KRAS VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 AREG TP53 VEGFA
5 liver development GO:0001889 9.8 HNF1B KRAS PIK3CA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 PIK3CA VEGFA
7 response to glucocorticoid GO:0051384 9.78 ACSBG1 AREG KRAS
8 positive regulation of MAP kinase activity GO:0043406 9.77 ERBB2 KRAS VEGFA
9 kidney development GO:0001822 9.71 HNF1B PAX8 VEGFA WT1
10 ERBB2 signaling pathway GO:0038128 9.65 ERBB2 KRAS PIK3CA
11 cytokine-mediated signaling pathway GO:0019221 9.63 AKT1 KRAS MMP2 PIK3CA TP53 VEGFA
12 anoikis GO:0043276 9.61 AKT1 PIK3CA
13 phosphatidylinositol 3-kinase signaling GO:0014065 9.61 AKT1 ERBB2 PIK3CA
14 cellular response to gonadotropin stimulus GO:0071371 9.6 PAX8 WT1
15 mesonephric tubule development GO:0072164 9.58 HNF1B PAX8
16 pronephros development GO:0048793 9.56 HNF1B PAX8
17 epidermal growth factor receptor signaling pathway GO:0007173 9.56 AKT1 AREG KRAS PIK3CA
18 metanephric S-shaped body morphogenesis GO:0072284 9.54 PAX8 WT1
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.54 BRCA1 BRCA2 TP53
20 metanephric epithelium development GO:0072207 9.52 PAX8 WT1
21 cellular response to indole-3-methanol GO:0071681 9.51 BRCA1 CDH1
22 positive regulation of gene expression GO:0010628 9.5 AKT1 BRCA1 ERBB2 HNF1B KRAS TP53
23 chordate embryonic development GO:0043009 9.49 BRCA1 BRCA2
24 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.46 HNF1B PAX8
25 positive regulation of transcription, DNA-templated GO:0045893 9.32 AKT1 ARID1A BRCA1 BRCA2 CDH1 HNF1B
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 AKT1 BRCA1 HNF1B PAX8 TP53 VEGFA

Molecular functions related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AKT1 AREG ARID1A BRCA1 BRCA2 CDH1
2 identical protein binding GO:0042802 9.7 AKT1 BRCA2 CDH1 CEACAM5 ERBB2 TP53
3 transcription regulatory region DNA binding GO:0044212 9.02 BRCA1 HNF1B PAX8 TP53 WT1

Sources for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....